www.condortherapeutics.com
Revolutionizing Critical Care
Condor Therapeutics is dedicated to the research and development of new generation Critical Care medicines, enhancing safety, precision, and patient experience through clinical innovation.
Our Mission
Condor Therapeutics is dedicated to revolutionizing Critical Care medicine through research-driven precision. Our mission is to enhance patient safety and experience by developing next-generation therapies that bridge the gap between preclinical research and real-world clinical outcomes. We are committed to clinical excellence and the advancement of medical science.
Safety
15+ Years R&D
Global Reach
Salus, Vita, Vigilantia
Leadership
Mr Michael Norster
mnorster@condortherapeutics.com
Non-Executive Chairman
Michael is a seasoned entrepreneur with a proven track record of scaling Australian start-ups to successful ASX listings and multi-million dollar exits. An expert in corporate strategy and renewable energy, he leverages his extensive background in law and science to drive commercial growth and investor value.
Dr Juliet Serrao
MB, BS, PhD, FRCA, GAICD
jserrao@condortherapeutics.com
Executive Director & Joint Founder
Juliet is a specialist clinician and PhD neuroscientist with global experience in anaesthesia and pain medicine. A prolific inventor, she developed the foundational IP for Condor, bridging the gap between clinical practice and cutting-edge pharmaceutical innovation.
Dr Colin Goodchild
MA (Cantab), MB, BChir, PhD, FRCA, FANZCA, FFPMANZCA
cgoodchild@condortherapeutics.com
Executive Director & Joint Founder
Colin is a Cambridge-educated clinician specialist in anaesthesia and pain medicine and a PhD neuroscientist with over 100 peer-reviewed publications in major international journals. As a co-inventor, his deep expertise in pharmacology and anesthesia drives the company's commitment to precision medicine and clinical excellence.